VentriPoint raises $1 million in debenture financing

VentriPoint Diagnostics Ltd., a Seattle-based provider of diagnostic tools to monitor patients with heart disease, announced it raised total proceeds of $1,052,317 in debenture financing. Health Canada has granted licensed approval for VentriPoint’s diagnostic tool which is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The diagnostic tool, together with its associated online service, is being developed for a variety of heart related diseases, including congenital heart disease and pulmonary hypertension.

Related external links (will open a new window):

  • Read more in the VentriPoint press release

    Related WTC links:

  • VentriPoint is a WTC client

    – end of post –

  • This entry was posted in Company_and_Client_News, Life_Sciences, RTD, UW, VentriPoint. Bookmark the permalink.

    Leave a Reply

    Fill in your details below or click an icon to log in:

    WordPress.com Logo

    You are commenting using your WordPress.com account. Log Out /  Change )

    Google photo

    You are commenting using your Google account. Log Out /  Change )

    Twitter picture

    You are commenting using your Twitter account. Log Out /  Change )

    Facebook photo

    You are commenting using your Facebook account. Log Out /  Change )

    Connecting to %s